- Email: [email protected]
Does First-Line Therapy Affect the Outcome of Patients with Pancreatic Cancer?
Annals of Oncology 25 (Supplement 4): iv210–iv253, 2014 doi:10.1093/annonc/mdu334.80
gastrointestinal tumours, non-colorectal 695P
M. Santoni1, A. Bittoni1, K. Andrikou1, A. Lanese1, C. Pellei1, A. Conti1, P. Bertocchi2, A.E. Brunetti3, M. Russano4, V. Vaccaro5, N. Silvestris6, M. Milella7, D. Santini4, A. Zaniboni8, S. Cascinu1 1 Clinica di Oncologia Medica, AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, ITALY 2 Oncologia Medica, Fondazione Poliambulanza, Brescia, ITALY 3 Medical Oncology, National Cancer Institute "Giovanni Paolo II", Bari, ITALY 4 Medical Oncology, Campus Bio-Medico di Roma, Rome, ITALY 5 Medical Oncology, Regina Elena National Cancer Institute, Rome, ITALY 6 Medical Oncology Unit, National Cancer Institute "Giovanni Paolo II", bari, ITALY 7 Divisione di Oncologia Medica A, Istituto Nazionale Tumori Regina Elena, Rome, ITALY 8 Oncology Department, Fondazione Poliambulanza, Brescia, ITALY
abstracts
Aim: A variety of cytotoxic agents, either alone or in combination, have been evaluated as first-line chemotherapies for patients ( pts) with locally advanced or metastatic
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv236/2241502 by guest on 24 October 2019
DOES FIRST-LINE THERAPY AFFECT THE OUTCOME OF PATIENTS WITH PANCREATIC CANCER?
pancreatic cancer. However, no standard of care exists. Aim of this study was to evaluate the prognostic significance of different first-line chemotherapies in pts with pancreatic ductal adenocarcinoma (PDAC). Methods: We retrospectively investigated clinical and laboratory data of pts treated with first-line chemotherapy for PDAC between January 2005 and April 2014 in four Italian institutions. Survival estimates were quantified using Kaplan Meier curves. Age, sex, ECOG-Performance Status (PS), tumor stage, pre-treatment CEA and CA 19-9 and first-line chemotherapy were included in the Cox analysis to investigate their prognostic relevance. Results: 479 pts were included in this analysis. Median age was 66 years (range 36-88); 274 pts were males (57%). Median overall survival (OS) was 7.9 months (range 0.3-60.8), while median PFS was 3.4 months (range 0.3-44.2). OS was 4.7, 7.5, 10.7 and 11.7 months in pts treated with gemcitabine (128 pts), gemcitabine and cisplatin/ oxaliplatin (216), gemcitabine and capecitabine (39) and Folfirinox (96), respectively ( p < 0.001). Similarly, PFS was 2.6, 3.0, 5.8 and 4.9 months ( p < 0.001). At multivariate analysis, tumor stage ( p < 0.001), ECOG-PS ≥ 2 ( p < 0.001) and choice of first-line chemotherapy ( p < 0.001) were independent prognostic factors for OS. Furthermore, ECOG-PS ≥ 2 ( p = 0.002) and choice of first-line chemotherapy ( p < 0.001) were independent predictors of PFS. Conclusions: Folfirinox regimen showed the highest OS and PFS as compared to gemcitabine alone or in combination with other agents as first-line therapy. The choice of first-line chemotherapy resulted an independent prognostic factor for both OS and PFS of pts with PDAC. Disclosure: All authors have declared no conflicts of interest.
gastrointestinal tumours, non-colorectal 695P
M. Santoni1, A. Bittoni1, K. Andrikou1, A. Lanese1, C. Pellei1, A. Conti1, P. Bertocchi2, A.E. Brunetti3, M. Russano4, V. Vaccaro5, N. Silvestris6, M. Milella7, D. Santini4, A. Zaniboni8, S. Cascinu1 1 Clinica di Oncologia Medica, AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, ITALY 2 Oncologia Medica, Fondazione Poliambulanza, Brescia, ITALY 3 Medical Oncology, National Cancer Institute "Giovanni Paolo II", Bari, ITALY 4 Medical Oncology, Campus Bio-Medico di Roma, Rome, ITALY 5 Medical Oncology, Regina Elena National Cancer Institute, Rome, ITALY 6 Medical Oncology Unit, National Cancer Institute "Giovanni Paolo II", bari, ITALY 7 Divisione di Oncologia Medica A, Istituto Nazionale Tumori Regina Elena, Rome, ITALY 8 Oncology Department, Fondazione Poliambulanza, Brescia, ITALY
abstracts
Aim: A variety of cytotoxic agents, either alone or in combination, have been evaluated as first-line chemotherapies for patients ( pts) with locally advanced or metastatic
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv236/2241502 by guest on 24 October 2019
DOES FIRST-LINE THERAPY AFFECT THE OUTCOME OF PATIENTS WITH PANCREATIC CANCER?
pancreatic cancer. However, no standard of care exists. Aim of this study was to evaluate the prognostic significance of different first-line chemotherapies in pts with pancreatic ductal adenocarcinoma (PDAC). Methods: We retrospectively investigated clinical and laboratory data of pts treated with first-line chemotherapy for PDAC between January 2005 and April 2014 in four Italian institutions. Survival estimates were quantified using Kaplan Meier curves. Age, sex, ECOG-Performance Status (PS), tumor stage, pre-treatment CEA and CA 19-9 and first-line chemotherapy were included in the Cox analysis to investigate their prognostic relevance. Results: 479 pts were included in this analysis. Median age was 66 years (range 36-88); 274 pts were males (57%). Median overall survival (OS) was 7.9 months (range 0.3-60.8), while median PFS was 3.4 months (range 0.3-44.2). OS was 4.7, 7.5, 10.7 and 11.7 months in pts treated with gemcitabine (128 pts), gemcitabine and cisplatin/ oxaliplatin (216), gemcitabine and capecitabine (39) and Folfirinox (96), respectively ( p < 0.001). Similarly, PFS was 2.6, 3.0, 5.8 and 4.9 months ( p < 0.001). At multivariate analysis, tumor stage ( p < 0.001), ECOG-PS ≥ 2 ( p < 0.001) and choice of first-line chemotherapy ( p < 0.001) were independent prognostic factors for OS. Furthermore, ECOG-PS ≥ 2 ( p = 0.002) and choice of first-line chemotherapy ( p < 0.001) were independent predictors of PFS. Conclusions: Folfirinox regimen showed the highest OS and PFS as compared to gemcitabine alone or in combination with other agents as first-line therapy. The choice of first-line chemotherapy resulted an independent prognostic factor for both OS and PFS of pts with PDAC. Disclosure: All authors have declared no conflicts of interest.